ClinicalTrials.gg
CompletedNCT01949324Updated Sep 12, 2018

A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel

A Phase 2 interventional study of Ciliary neurotrophic factor (CNTF) and Sham procedure in Macular Telangiectasia Type 2, sponsored by Neurotech Pharmaceuticals. Completed at 11 sites in 2 countries. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-09-12.

Sponsored by Neurotech Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2017, 9 years 7 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in May 2018.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 33 studies in Telangiectasis with a site in United States — 5 open to participants now, 5 under way, 2 of them phase 3. Telangiectasis · United States.

Enrollment
8th of 31
67 · median 20
Started
2014
with 2 others
Phase 2
7 of 33
none open now
Registered
14th of 33
by date
Lead sponsor
7 of 33
Neurotech Pharmaceuticals

Among the 33 studies in Telangiectasis with a site in United States, this one is the 8th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2014, is one of 7 in phase 2, and was the 14th registered.

Telangiectasis

69 studies on the registry are indexed under Telangiectasis; 12 are open to participants now.

Browse Telangiectasis studies →

Open to participants now

5 of the 33 studies in Telangiectasis with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Telangiectasis studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Telangiectasis with a site in United States, or all of them as a file.
02

Study summary

This study is a phase 2, randomized, multi-center, single-masked study to evaluate the efficacy and safety of the NT-501 implants in participants with Mactel.

03

Conditions studied

  • Macular Telangiectasia Type 2

Browse trials for

Keywords

  • MacTel
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be offered sufficient opportunity to review and to understand the form, agree to the form's contents and sign the protocol's informed consent
  • Participant must have at least one study eye with a positive diagnosis of MacTel Type 2
  • Participant must have an IS/OS PR break in the study eye(s) and en face ellipsoid zone (area of IS/OS loss) as measured by SDOCT between 0.16 mm2 and 4.00 mm2
  • If female, participant must be incapable of pregnancy
  • If male, participant must agree to use an effective form of during the study

Exclusion criteria

Exclusion Criteria:

  • Participant is unable to provide
  • Participant is less than 21 years of age or greater than 80 years of age
  • Participant is medically unable to comply with study procedures or follow-up visits
  • Participant was a study subject in any other clinical trial of an intervention (drug or device) within the last 6 months
  • Participant is pregnant or breastfeeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    NT-501 Implant procedure

    The investigational product is the NT-501 encapsulated cell system which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that were derived from the NTC-200 cell line by genetic modification so as to secrete recombinant human ciliary neurotrophic factor (CNTF).

    Biological: Ciliary neurotrophic factor (CNTF) · Device: NT-501 Implant · Procedure: NT-501 Implant procedure

  • Sham comparator
    Sham procedure

    Non-penetrating sham procedure to mimic implant procedure

    Procedure: Sham procedure

Interventions

  • Ciliary neurotrophic factor released from NT-501 encapsulated cell implant

  • ProcedureSham procedure

    Sham surgery for Sham arm

  • DeviceNT-501 Implant

    NT-501 encapsulated cell implant

  • ProcedureNT-501 Implant procedure

    Surgery to implant device for NT-501 encapsulated cell implant releasing human ciliary neurotrophic factor arm

06

What researchers measure

Primary outcomes

  1. Ellipsoid zone (area of IS/OS loss) as measured by en face imagining by SDOCT in study eye(s)

    Change in the ellipsoid zone (area of IS/OS loss) from baseline to month 24 as measured by en face imaging by SDOCT in study eye(s)

    Time frame: 24 months

Secondary outcomes

  1. Ellipsoid zone

    Change in the ellipsoid zone from baseline to Month 12.

    Time frame: 12 months

  2. Retinal sensitivity (dB) as measured by microperimetry

    Change in retinal sensitivity (dB) as measured by microperimetry from baseline to Months 12 and 24.

    Time frame: 12 and 24 months

  3. Increase in ellipsoid zone

    Proportion of study eyes with a 35% or more increase from baseline in the ellipsoid zone at Months 12 and 24.

    Time frame: 12 and 24 months

  4. Visual Acuity

    Change in best corrected visual acuity (BCVA) from baseline to Months 12 and 24.

    Time frame: 12 and 24 months

  5. Visual Acuity

    Proportion of study eyes with 15 or more letter loss from baseline in BCVA at Months 12 and 24.

    Time frame: 12 and 24 Months

  6. Visual Acuity

    Proportion of study eyes with 10 or more letter loss from baseline in BCVA at Months 12 and 24.

    Time frame: 12 and 24 Months

  7. Reading Speed

    Change in reading speed as measured by the IReST from baseline to Months 12 and 24.

    Time frame: 12 and 24 Months

Other outcomes

  1. Cone density as measured by AOSLO

    Change in cone density as measured by AOSLO from baseline to Months 12 and 24, in selected participants.

    Time frame: 12 and 24 Months

  2. National Eye Institute Visual Functioning Questionnaire

    Change in NEI VFQ (overall and subscale) from baseline to Months 12 and 24.

    Time frame: 12 and 24 months

  3. Electroretinogram changes

    Electroretinogram (ERG) changes from baseline to Months 6, 12 and 24, in selected clinics/participants.

    Time frame: 6, 12 and 24 Months

07

Study locations

11 sites
  • Jules Stein Eye Institute
    Los Angeles, California 90095, United States
  • Bascom Palmer
    Miami, Florida 33136, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • National Eye Institute
    Bethesda, Maryland 20892, United States
  • Massachusetts Eye and Ear Infirmary, Retina Service
    Boston, Massachusetts 02114, United States
  • University of Michigan, Kellogg Eye Center
    Ann Arbor, Michigan 48105, United States
  • Retina Associates of Cleveland, Inc.
    Beachwood, Ohio 44122, United States
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
  • Save Sight Institute
    Sydney, New South Wales, Australia
  • Centre for Eye Research Australia
    East Melbourne, Australia
  • Lions Eye Institute
    Nedlands, Australia
08

References and documents

Publications

  • Loo J, Cai CX, Choong J, Chew EY, Friedlander M, Jaffe GJ, Farsiu S. Deep learning-based classification and segmentation of retinal cavitations on optical coherence tomography images of macular telangiectasia type 2. Br J Ophthalmol. 2022 Mar;106(3):396-402. doi: 10.1136/bjophthalmol-2020-317131. Epub 2020 Nov 23. PubMed 33229343 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Apr 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2013
First posted
Sep 24, 2013
Start
Apr 2014
Primary completionActual
Apr 14, 2017
CompletionActual
May 22, 2017
Results delay requested
May 4, 2018
Last update
Sep 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01949324
Lead sponsor
Neurotech Pharmaceuticals
Collaborators
The Lowy Medical Research Institute Limited, The Emmes Company, LLC
Responsible party
Sponsor
First posted
Sep 24, 2013
Start date
Apr 2014
Primary completion
Apr 14, 2017
Completion
May 22, 2017
Last update
Sep 12, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciliary Neurotrophic Factor

Start the discussion